VERV NASDAQ
Boston, MA 02139
US
Verve Therapeutics, Inc. is a biotechnology firm dedicated to pioneering gene-editing treatments for individuals afflicted with cardiovascular diseases. Their flagship experimental therapy, VERVE-101, represents a singular gene-editing intervention engineered to irreversibly inactivate the PCSK9 gene within the liver. The company is also progressing with an ANGPTL3 program, which similarly aims to permanently switch off the ANGPTL3 gene in the liver. To support its endeavors, Verve maintains several key partnerships, including a collaboration and licensing pact with Beam Therapeutics Inc., a development and option agreement with Acuitas Therapeutics, Inc., and a Cas9 gene-editing technology license from The Broad Institute and the President and Fellows of Harvard College. Incorporated in 2018 and headquartered in Cambridge, Massachusetts, the organization operated under the name Endcadia, Inc. until its rebranding to Verve Therapeutics, Inc. in January 2019.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| GV 2017 GP, L.L.C. | U-Tender | 1,800,000 | $10.50 | 2025-07-25 |
| MacLean Michael F | D-Return | 136,139 | $5.02 | 2025-07-25 |
| MacLean Michael F | D-Return | 42,200 | $5.73 | 2025-07-25 |
| Yeshwant Krishna | D-Return | 136,139 | $5.02 | 2025-07-25 |
| Yeshwant Krishna | D-Return | 42,200 | $5.73 | 2025-07-25 |